OptiMed Introduces SPRAVATO® Treatment Service for Treatment-Resistant Depression in Munster, Indiana

OptiMed HealthCare Partners has announced the opening of a new center in Munster, Indiana, providing SPRAVATO® treatment services. SPRAVATO® is the first FDA-approved nasal spray for treatment-resistant depression (TRD). This new service aims to address the mental health needs of the Northwest Indiana and Chicagoland area.

SPRAVATO®, also known as esketamine, offers a new approach for individuals who have not responded to conventional antidepressants. It is administered under medical supervision and used in conjunction with oral antidepressants. Short-term clinical studies have shown a significant reduction in depressive symptoms in as little as 24 hours.

OptiMed is committed to enhancing mental health and removing barriers to treatment. Michael J. Lane, DNP, MSN, PMHNP-BC, APRN, emphasized the importance of dedication to underserved communities and supporting those struggling with mental health issues.

Patients interested in SPRAVATO® treatment can contact OptiMed through phone or email, with staff available to assist in scheduling and providing further information. OptiMed believes in the positive impact of SPRAVATO® and looks forward to supporting patients on their mental health journeys.